Congenital Zika Syndrome

Congenital Zika syndrome (CZS) is a distinct pattern of congenital structural anomalies and functional neurodevelopmental impairments caused by vertical intrauterine transmission of Zika virus (ZIKV; species Orthoflavivirus zikaense, family Flaviviridae) from an infected pregnant person to the developing embryo or fetus. First recognized between August and November 2015 in Northeast Brazil—centered in the states of Pernambuco, Bahia, and Paraíba—when pediatric neurologists and fetal medicine specialists including Vanessa van der Linden, Adriana Melo, and Celina Martelli together with the Microcephaly Epidemic Research Group (MERG) linked a cluster of newborn microcephaly cases to the ongoing Aedes aegypti–borne Zika epidemic, the syndrome prompted the World Health Organization to declare a Public Health Emergency of International Concern in February 2016. Unlike classic TORCH teratogens (Toxoplasma gondii, rubella virus, cytomegalovirus, and herpes simplex virus), Zika virus displays selective neurotropism for embryonic cortical radial glial neural progenitor cells, producing destructive fetal brain arrest alongside pathognomonic ocular and musculoskeletal malformations even when maternal infection is asymptomatic.

The 2015–2016 Northeast Brazilian Cluster

Prior to 2015, Zika virus had been regarded for six decades as a benign, self-limiting febrile illness before sweeping from Micronesia (Yap Island, 2007) and French Polynesia (2013–2014) into South America. Following its introduction into northeastern Brazil between 2013 and 2014, intense urban transmission mediated by domestic Aedes aegypti coincided with a 20-fold surge in neonates born with craniofacial disproportion and cerebral calcifications in Recife (Pernambuco), Campina Grande (Paraíba), and Salvador (Bahia). In November 2015, Adriana Melo demonstrated ZIKV genomic RNA by reverse transcription-polymerase chain reaction (RT-PCR) in the amniotic fluid of two pregnant women from Paraíba whose fetuses exhibited ultrasound-confirmed microcephaly and ventriculomegaly, while case-control studies conducted by Celina Martelli and the Microcephaly Epidemic Research Group confirmed the causal teratogenic association (with adjusted odds ratios exceeding 50 for laboratory-confirmed ZIKV infection). Between 2015 and 2017, Brazil confirmed more than 3,500 cases of congenital Zika syndrome, with additional clusters documented in Colombia, Venezuela, Suriname, and French Guiana.

Trimester-Specific Risk and Transmission Rates

Vertical maternal-fetal transmission of Zika virus can occur during any trimester of pregnancy regardless of whether the pregnant mother experiences symptomatic rash and fever or an asymptomatic infection. Prospective cohort studies across Rio de Janeiro, Recife, and French Guiana established two key epidemiological parameters:

• Vertical transmission rate: Approximately 20 to 30 percent of maternal ZIKV infections result in transplacental fetal infection.
• Gestational age dependency of teratogenesis: The risk of structural congenital anomalies is highest when maternal infection occurs during the first trimester (weeks 1 to 13 of gestation, carrying an 8 to 15 percent risk of microcephaly and structural brain defects) or early second trimester, corresponding to the peak window of cortical neurogenesis and neuronal migration. Third-trimester infections rarely produce gross microcephaly at birth but can cause subtle white-matter lesions, delayed postnatal head growth, chorioretinal lesions, or neurodevelopmental deficits appearing during infancy.

Hofbauer Cell Infection and Transplacental Passage

To reach the fetal circulation, Zika virus must breach the human hemochorial placenta, whose outer syncytioblast layer resists most viral infections through constitutive secretion of type III interferons (IFN-λ1 and IFN-λ2). ZIKV circumvents this barrier during early gestation by infecting extravillous cytotrophoblasts, placental endothelial cells, and fetal-derived placental macrophages located within the chorionic villous stroma known as Hofbauer cells. Within Hofbauer cells, ZIKV replicates productively without inducing rapid cytolysis, using these migratory macrophages as a permissive reservoir that releases virions directly into fetal villous capillaries. Experimental studies also indicate that pre-existing cross-reactive maternal IgG antibodies elicited by prior dengue fever can bind ZIKV virions and mediate neonatal Fc receptor (FcRn)–dependent transcytosis across the syncytiotrophoblast, linking placental entry dynamics to mechanisms of antibody-dependent enhancement in dengue.

Radial Glial Neural Progenitor Tropism and Autophagy Dysregulation

Once inside the fetal bloodstream, Zika virus crosses the immature blood-brain barrier and blood-retinal barrier to target radial glial cells—the primary neural progenitor cells (NPCs) of the embryonic ventricular and subventricular zones that generate cortical excitatory neurons and provide the radial scaffolding for outward neuronal migration. Attachment and entry into radial glial NPCs, astrocytes, and retinal pigment epithelial cells are facilitated by phosphatidylserine-binding TAM and TIM family receptors, particularly AXL, TYRO3, and TIM-1, as well as neural cell adhesion molecule (NCAM1) and integrin α_vβ₅.

Intracellularly, viral replication disrupts embryonic corticogenesis through three converging molecular mechanisms:

1. NS4A and NS4B inhibition of Akt–mTOR signaling: The non-structural proteins NS4A and NS4B cooperatively suppress phosphorylation of Akt and mechanistic target of rapamycin (mTOR) in human fetal neural stem cells, prematurely inducing host autophagy to divert cellular membranes toward endoplasmic reticulum viral replication vesicles while halting neurogenesis.
2. Centrosomal amplification and mitotic arrest: Viral NS2B–NS3 protease cleavage of host septins and perturbation of centrosomal proteins (such as CEP152 and pericentrin) cause multipolar spindle assembly, chromosomal lagging, aneuploidy, and G2/M cell-cycle arrest in dividing radial glia.
3. Toll-like receptor 3 (TLR3) and p53-mediated apoptosis: Double-stranded viral RNA replication intermediates hyperactivate endosomal TLR3 and nuclear tumor suppressor p53 pathways, triggering widespread caspase-3–mediated apoptosis of cortical progenitors and immature migrating neuroblasts.

In 2016, Cynthia Moore, Vanessa van der Linden, and colleagues defined five clinical and neuroimaging features that, in combination, distinguish congenital Zika syndrome from other congenital infections and genetic microcephalies:

Long-Term Neurodevelopmental and Endocrine Sequelae

Children born with congenital Zika syndrome face complex lifelong morbidities requiring multidisciplinary care. Over 60 to 80 percent of affected children with microcephaly develop drug-resistant epilepsy—frequently presenting in the first year of life as infantile spasms (West syndrome) or focal motor seizures—alongside sensorineural hearing loss (affecting 6 to 12 percent of patients), cortical visual impairment, neurogenic bladder dysfunction, and pharyngeal dysphagia predisposing to recurrent aspiration pneumonia. Notably, longitudinal follow-up of normocephalic infants exposed to ZIKV in utero has revealed that a subset develops postnatal-onset microcephaly, autism spectrum traits, or language and motor delays by 2 to 3 years of age.

Prenatal Ultrasound, Neuroimaging, and Virological Testing

Prenatal suspicion arises on serial obstetric ultrasonography—typically detectable from 18 to 24 weeks of gestation onward—showing decelerating fetal head circumference growth, ventriculomegaly, linear or punctate subcortical calcifications, cerebellar vermis hypoplasia, and arthrogryposis. Fetal and neonatal cranial computed tomography (CT) and magnetic resonance imaging (MRI) delineate the characteristic calcifications at the cortical-subcortical junction (distinct from the periventricular calcifications typical of congenital cytomegalovirus).

Laboratory confirmation in the neonate combines:

• Molecular detection: Real-time RT-qPCR for ZIKV RNA in neonatal serum, urine, and cerebrospinal fluid (CSF) collected within the first 48 hours of life.
• Serological confirmation: Detection of anti-ZIKV IgM antibodies in neonatal CSF or serum by MAC-ELISA (as maternal IgM does not cross the placenta), supplemented by plaque reduction neutralization testing (PRNT) to distinguish ZIKV from dengue virus.

Multidisciplinary Supportive Care

Because no specific antiviral therapy reverses established embryonic neural loss, clinical management is supportive and initiated immediately after birth. Infants require comprehensive ophthalmological fundoscopy, auditory brainstem response (ABR) screening, electroencephalography (EEG), electrophysiologic swallowing evaluation (often necessitating gastrostomy tube placement for severe dysphagia), orthopedic casting or tenotomy for clubfoot and arthrogryposis, antispasticity pharmacotherapy (baclofen or botulinum toxin injections), and targeted antiepileptic regimens. Primary prevention centers on protecting pregnant individuals in endemic regions from Aedes aegypti bites, screening blood donations, counseling against unprotected sexual exposure to partners returning from ZIKV transmission zones, and deploying Wolbachia-based vector control.

How do the brain calcifications of congenital Zika syndrome differ from congenital cytomegalovirus?

While congenital cytomegalovirus (CMV) characteristically produces calcifications lining the ependymal surface of the lateral ventricles (periventricular distribution), Zika virus preferentially destroys migrating neuroblasts and radial glia at the corticomedullary border, resulting in a linear or punctate band of calcifications specifically along the junction between the cerebral cortex and subcortical white matter, accompanied by variable calcifications in the basal ganglia and thalamus.

What is the fetal brain disruption sequence in congenital Zika syndrome?

Fetal brain disruption sequence occurs when an embryonic brain that initially expanded normally during early gestation undergoes sudden parenchymal destruction and arrest of cerebrospinal fluid production. As intracranial volume collapses, the pliable fetal calvarium implodes inward, producing overlapping cranial sutures, a prominent occipital bone shelf, and redundant folds of scalp skin that continued to grow before arrest.

Can an infant have congenital Zika syndrome if born with a normal head circumference?

Yes. When maternal ZIKV infection occurs during the late second or third trimester after primary cranial vault expansion has occurred, neonates may be born with a normal head circumference yet harbor macular chorioretinal scarring, subcortical white-matter lesions, sensorineural hearing loss, or postnatal-onset microcephaly and neurodevelopmental delay emerging during the first two years of life.

1. Mlakar, J., Korva, M., Tul, N., et al. (2016). Zika Virus Associated with Microcephaly. New England Journal of Medicine, 374(10), 951–958. doi:10.1056/NEJMoa1600651
2. Brasil, P., Pereira, J. P., Moreira, M. E., et al. (2016). Zika Virus Infection in Pregnant Women in Rio de Janeiro. New England Journal of Medicine, 375(24), 2321–2334. doi:10.1056/NEJMoa1602412
3. Tang, H., Hammack, C., Ogden, S. C., et al. (2016). Zika Virus Infects Human Cortical Neural Progenitors and Attenuates Their Growth. Cell Stem Cell, 18(5), 587–590. doi:10.1016/j.stem.2016.02.016
4. Liang, Q., Luo, Z., Zeng, J., et al. (2016). Zika Virus NS4A and NS4B Proteins Deregulate Akt-mTOR Signaling in Human Fetal Neural Stem Cells to Inhibit Neurogenesis and Induce Autophagy. Cell Stem Cell, 19(5), 663–671. doi:10.1016/j.stem.2016.07.019
5. de Araújo, T. V. B., Rodrigues, L. C., de Alencar Ximenes, R. A., et al. (2016). Association between Zika virus infection and microcephaly in Brazil, January to May, 2016: preliminary report of a case-control study. The Lancet Infectious Diseases, 16(12), 1356–1363. doi:10.1016/S1473-3099(16)30318-830318-8)
6. Moore, C. A., Staples, J. E., Dobyns, W. B., et al. (2017). Characterizing the Pattern of Anomalies in Congenital Zika Syndrome for Pediatric Clinicians. JAMA Pediatrics, 171(3), 288–295. doi:10.1001/jamapediatrics.2016.3982